On March 22, 2022, all study sites have met the criteria to provide treatment in the cross-over extension study for MAPS-sponsored Phase 3 trials of MDMA-assisted therapy for posttraumatic stress disorder …
On February 3, our Phase 3 study site for MDMA-assisted psychotherapy for PTSD in Tel Hashomer, Israel, officially opened for phone screenings and informed consent visits. Led by Principal Investigator …
Our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD is well underway, with enrollment of more than two-thirds of the participants needed to complete the study. We have also begun our long …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. We’ve already accrued about 57 of the 100 subjects needed so potential volunteers …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers must have PTSD and live in an area close to a study site. People of color …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers must have PTSD and live in an area close to a study site. Volunteers will …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers must have PTSD and live in an area close to a study site. Volunteers will …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers will help contribute to scientific knowledge and will help us better understand …
On June 11, 2021, the first participant in Be’er Ya’akov (Merhavim), Israel, was enrolled in our randomized, double-blind, placebo-controlled, multi-site Phase 3 study of the efficacy and safety of …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers will help contribute to scientific knowledge and will help us better understand …
On May 3, 2021, we announced that the first Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) which replicated and expanded on Phase 2 results indicates that MDMA-assisted …
